EQL has entered into an exclusive license agreement for the French market for EQL's product Memprex with Laboratoires Majorelle. Memprex is a methenamine hippurate-based medicine indicated for the prophylaxis of recurrent urinary tract infection. Methenamine hippurate was launched by EQL in Sweden in 2019, in the UK (via partner) in 2020 and in Norway in 2021.

EQL's ambition is to offer Methenamine, using own brand Memprex, to all other interesting markets in Europe via out-licensing. Methenamine hippurate is the only substance that is non-inferior to antibiotics as a prophylactic to recurrent UTI while at the same time not increasing the risk for developing antibiotic resistant bacteria in the patient. Resistant E coli bacteria which are behind most UTI's is the most fatal among multidrug resistant bacteria.